At Matrivax, we are developing effective vaccines to address three of these concerning threats:

Urgent threat – C. difficile

Serious threat – S. pneumoniae, drug resistant

Serious threat – S. Typhi, drug resistant

22 views0 comments
  • Nicole Ruggiero

Dr. Killeen (CEO) will be presenting at Vaccines Research And Development, November 19, 2019, at the Crowne Plaza Boston.

12:10-12:35 Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse. Kevin Killeen, Chief Scientific Officer, Matrivax R&D Corp

39 views0 comments